Organ announces that it is reopening consultations on the medical use of the substance; the resolution published last week, with more restrictions than the previous text, has generated controversy
or Federal Council of Medicine (FCM) announced at the end of the afternoon of this Thursday 20, that the public consultation will reopen to the population to receive contributions for the updating of resolution 2.324 / 2022, which deals with criteria for prescribing medicinal cannabidiol (CBD) in the country. The resolution released last Friday made CBD prescribing even more restrictive than the previous resolution, from 2014, sparking great controversy.
Under the new council rules, doctors can only prescribe CBD for the treatment of certain types of epilepsy and only if good results are not achieved with traditional treatments. The decision came at a time when CBD prescription is becoming more and more common for different types of problems such as depression, chronic pain, fibromyalgia.
With the announcement of the reopening of the public consultation – this time not only for doctors, but for the entire population – anyone will be able to send contributions to the debate, between 24 October and 23 December. This is the first step in revising the entire resolution. Doctors and agencies had already announced that they would continue to prescribe CBD regardless of the CFM decision.
In the note released this Thursday afternoon, the CFM justified itself. He recalled that more than 6,000 scientific articles on the subject have been evaluated and hundreds of professionals consulted. The council added that it bases its decisions on evidence-based medicine.
“The conclusions point to still fragile evidence on the safety and efficacy of cannabidiol for the treatment of most diseases, and there are scientific studies with confirmed positive results only for cases of seizures related to Dravet, Doose and Lennox-Gastaut syndromes. “, the note reads.
The press release also adds that the council plenary considers it “prudent to wait for the progress of the studies in progress, the results of which will expand – or not – the perception of the efficacy and safety of cannabidiol, avoiding exposing the population to risk situations”. or The Federal Public Ministry (MPF) has questioned the CFM in this regard, and the institution declares that it will transmit all the information requested.
The associations issue a note
In a note published on Thursday, five associations ruled against the CFM’s decision, they were: Brazilian Association of the Pharmaceutical Input Industry (ABIQUIFI), Brazilian Association of Fine Chemicals, Biotechnology and Specialty Industries (ABIFINA), Association of Companies in the herbal and food sector Supplements and health promotion sector (ABIFISA), the Brazilian Association of Representative Clinical Research Organizations (Abracro) and the Brazilian Association of Cannabinoid Industries (BRCann).
According to the institutions, medical autonomy should be fundamental in the recommendation of the substance and they fear damage to the continuity of care already underway.
The manifesto also criticizes the council’s prohibitions on physicians to mention the component in conferences and courses on the subject. “Restricting the spaces in which professionals can speak means placing barriers to the dissemination of scientific knowledge and impediments to the promotion of research”, reads the text, which continues: “Another harmful consequence of the proposed resolution is the possibility of limiting development of science and new study protocols “.
According to the associations, the use of cannabinoids is extensively tested in the treatment of diseases such as multiple sclerosis, in palliative care for cancer and even in mental health conditions, such as autism. Furthermore, the recombination of its elements can further increase the benefits of the plant extract.
The note concludes by warning about the risk of restricting the social participation of patients, families, health professionals, researchers and companies in the development of products of natural origin and suggests new technical discussions with the junta on the substance.
“We cannot ignore ongoing treatments that have been successful in the therapeutic response. For the well-being of patients and scientific progress, the institutions make themselves available to the Federal Council of Medicine and understand that the opening of dialogue is appropriate” , closes the poster. / COLLABORATE FABIO TARNAPOLSKY, SPECIAL FOR ESTADÃO
+The best content in your email for free. Choose your favorite Earth Newsletter. Click here!
Source: Terra
Benjamin Smith is a fashion journalist and author at Gossipify, known for his coverage of the latest fashion trends and industry insights. He writes about clothing, shoes, accessories, and runway shows, providing in-depth analysis and unique perspectives. He’s respected for his ability to spot emerging designers and trends, and for providing practical fashion advice to readers.
